What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?

What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?

CLICK HERE FOR CME CREDIT Back to Symposium

What the “therapeutic ladder” for AD in the pediatric and adolescent group, and what is the trigger for systemic immunotherapy? Where does dupilumab-mediated, type 2 cytokine-targeting fit into your approach to AD in the younger population?

Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Peter Lio, MD

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois